Navigation Links
The Galien Foundation Celebrates Biomedical Innovation in Fourth Galien Forum
Date:7/9/2013

NEW YORK, July 9, 2013 /PRNewswire/ -- The Galien Foundation today announced the formal program of presenters and panels for its Fourth Galien Forum, scheduled for Tuesday, October 22, 2013 at the Alexandria Life Sciences Center in New York City.  The Galien Forum, conducted in conjunction with the prestigious Prix Galien Awards, features roundtable debates focusing on critical, global healthcare issues and challenges.  This year's program includes a panel of current industry CEOs tackling the impact of the Affordable Care Act on the biopharmaceutical industry: Ken Frazier (Merck), Alex Gorsky (Johnson & Johnson) and Dr. John Lechleiter (Eli Lilly & Company), moderated by P. Roy Vagelos, M.D. (Chairman of Regeneron Pharmaceuticals and retired Chairman and CEO at Merck).

(Logo: http://photos.prnewswire.com/prnh/20130709/NY43872LOGO )

The Keynote Session will be offered by the renowned Bert Vogelstein, M.D., Professor of Oncology and Pathology, Investigator, Howard Hughes Medical Institute; Director, Ludwig Center for Cancer Genetics & Therapeutics at Johns Hopkins School of Medicine. Long recognized as a "giant of science…whose work has been most influential over the past 20 years," according to The Guardian, Dr. Vogelstein explores the genetic causes of cancer.

Joel S. Marcus, Chairman, Alexandria and Neil de Crescenzo, General Manager, Oracle Health Sciences, long-time supporters of the Galien Foundation mission, will welcome participants.

"In this our Fourth Galien Forum, we are again so honored to have attracted biopharmaceutical leaders, researchers, clinicians and health policy experts at the very top of their fields to contribute their expertise and wisdom to our program," commented Bruno Cohen, Galien Foundation Chairman.  "These annual dialogues continue to demonstrate that it is only through coming together for conversations and working collaboratively that we will be able to address the challenging global healthcare issues facing scientific, medical and technological innovation."

This year, The Galien Forum explores the need for and challenges facing enhanced Industry-academia interactions in a panel including:

  • Dr. Christopher Austin, Director, National Center for Advancing Translational Sciences – National Institutes of Health
  • Dr. Michael S. Brown, Regental Professor, University of Texas Southwestern Medical Center
  • Dr. Robert M. Califf, Vice Chancellor for Clinical and Translational Medicine, Duke University
  • Dr. John Thomas Potts, Jr., Neuroendocrine Clinical Center, Harvard Medical Scholl
  • Dr. Michael Rosenblatt, Executive Vice President and Chief Medical Officer, Merck, who will serve as panel moderator.

The Galien Foundation also disclosed today that nomination submissions for the 2013 Prix Galien USA Awards are actively continuing, with final candidates to be announced shortly.  The Prix Galien Awards represent the highest accolade for research and development – the biomedical industry's equivalent of the Nobel Prize.

"The focus of biomedical innovation must be major improvement in the patient's welfare: prolongation of life, less need for hospitalization, quality of life, ability to continue normal life activities," commented P. Roy Vagelos, M.D., Chairman of Regeneron Pharmaceuticals, retired Chairman and Chief Executive Officer of Merck and chair of the Prix Galien USA Awards Committee.  "Interdisciplinary collaborations starting with target identification, product discovery and candidate selection, clinical characterization and product launch all pull together the full strengths of the industry to improve outcomes for patients.  Real success is improved patient health and ultimately decreased health care costs."

About the Galien Foundation and the Prix Galien Awards

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information visit www.galienfoundation.org.

Galien Foundation Media Contact:
Jon Florio
Makovsky
jflorio@makovsky.com
212-508-9667

 


'/>"/>
SOURCE Galien Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
2. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
3. The Sidney Kimmel Foundation for Cancer Research Announces 2013 Grant Recipients
4. OU professor recipient of grant from the Simons Foundation Fellows Program in Theoretical Physics
5. The Research Foundation for The State University of New York Enters Site License Agreement with 2Market Information Inc., Publisher of Technology Transfer Tactics
6. Wysebridge Patent Bar Review Supports the National Foundation for Celiac Awareness (NFCA) During Celiac Awareness Month
7. Save The Cord Foundation, a Global Leader in Cord Blood Advocacy, Announces its Expansion of Educational Information Surrounding Other Non-Controversial Stem Cell Sources
8. Coulter Foundation Surprises Westminster College With One Million Dollar Gift
9. Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimers Disease Patients
10. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
11. Arthritis Foundation Announces Appointment of John Vernachio As Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... York (PRWEB) , ... February ... ... (NASDAQ: REGN) today announced that it has joined the Human Vaccines Project, ... for infectious diseases and cancer. , The Human Vaccines Project brings ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading ... (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. ... tables for its annual event, which will run from 3:00 p.m. - 8:30 ...
(Date:2/10/2016)... FL (PRWEB) , ... February 10, 2016 , ... ... in regenerative medicine, has announced a new agreement with Singapore-based Global Stem Cells ... physicians from the Philippines, Thailand and Singapore in the latest adipose and bone ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date and time: ... Institute at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old Easton Road, ... College (TCMC) will hold an open house for participants to learn about a ...
Breaking Biology Technology:
(Date:2/9/2016)... Vigilant Solutions announces today that an agency used its Vigilant ... in a difficult homicide case. The agency then used Vigilant,s ... vehicle. Due to the ongoing investigation, the agency name and ... agency,s request. --> --> ... deceased at an intersection here in the City. He had ...
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... with fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... --> --> January to ... up 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
Breaking Biology News(10 mins):